Jinne Richards, MD
Adult Medicine · Albany, GANPI 1497162325
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 675 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among adult medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 675 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$1K
- AstraZeneca$840
- AbbVie$766
- Pfizer$699
- Bayer$608
- plus $5K from 39 others
Across 7 payments — averaging $10,654 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$75K
What the payments were for
- Food & beverage$10,63599%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,751 in reported general payments places this provider in the 95th percentile of 43 adult medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $133,099 |
| EliquisApixaban | 181 | $129,380 |
| FarxigaDapagliflozin Propanediol | 124 | $99,929 |
| KerendiaFinerenone | 56 | $56,707 |
| MounjaroTirzepatide | 45 | $51,014 |
| TrulicityDulaglutide | 46 | $50,053 |
| XareltoRivaroxaban | 51 | $33,718 |
| LinzessLinaclotide | 31 | $25,518 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $22,667 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,963 |
| MyrbetriqMirabegron | 23 | $16,541 |
| JanuviaSitagliptin Phosphate | 21 | $13,623 |
| JardianceEmpagliflozin | 11 | $11,422 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $9,960 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $1,288 | $136,573128 claims |
| PfizerEliquis | $699 | $129,380181 claims |
| AstraZenecaFarxiga, Symbicort | $840 | $102,667136 claims |
| Lilly USA, LLCMounjaro, Trulicity | $502 | $101,06791 claims |
| BayerKerendia | $608 | $56,70756 claims |
| MerckJanumet, Januvia | $78 | $36,29045 claims |
| Johnson & JohnsonXarelto | $83 | $33,71851 claims |
| GSKTrelegy Ellipta, Shingrix | $1,379 | $28,04762 claims |
| AbbVieLinzess, Synthroid | $766 | $27,25181 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $539 | $20,58029 claims |
| Astellas Pharma US IncMyrbetriq | $493 | $16,54123 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $1,478154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 adult medicine providers in Georgia.
Other adult medicine in Albany
- Michael CohenPooler$14K
- Charles WilliamsAlpharetta$10K
- Kenneth JonesUnion City$9K
- Katherine McClellanRinggold$7K
- Ewaul PersaudSmyrna$6K
- Jenna Barnes CaronDalton$5K
- Alana VilladaBuford$4K
- Syed UllahDecatur$4K
- Wylie NewtonGainesville$3K
- Leah ReedCumming$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.